A registry-based non-interventional post-authorization safety study to evaluate the long-term safety of dupilumab in children aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis using the PEDISTAD registry: a cohort design First published 08/05/2024 Last updated 10/03/2025 EU PAS number:EUPAS1000000149 Study Ongoing